Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer
Launched by CORPORACION PARC TAULI · Mar 28, 2017
Trial Information
Current as of September 07, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with resectable advanced gastric cancer
- • Informed consent
- Exclusion Criteria:
- • Macroscopic peritoneal carcinomatosis
- • Non operable patients
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sabadell, Barcelona, Spain
Patients applied
Trial Officials
Alexis Luna, MD PhD
Principal Investigator
Corporación Parc Taulí
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials